516 related articles for article (PubMed ID: 33086126)
1. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
2. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.
Tai S; Fantegrossi WE
Curr Top Behav Neurosci; 2017; 32():249-262. PubMed ID: 28012093
[TBL] [Abstract][Full Text] [Related]
4. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Galaj E; Xi ZX
CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.
Tai S; Fantegrossi WE
Curr Addict Rep; 2014 Jun; 1(2):129-136. PubMed ID: 26413452
[TBL] [Abstract][Full Text] [Related]
8. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
[TBL] [Abstract][Full Text] [Related]
9. The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species.
Borgan F; Beck K; Butler E; McCutcheon R; Veronese M; Vernon A; Howes OD
Psychopharmacology (Berl); 2019 Nov; 236(11):3257-3270. PubMed ID: 31165913
[TBL] [Abstract][Full Text] [Related]
10. Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201.
AlKhelb D; Burke EL; Zvonok A; Iliopoulos-Tsoutsouvas C; Georgiadis MO; Jiang S; Ho TC; Nikas SP; Makriyannis A; Desai RI
Eur J Pharmacol; 2023 Dec; 960():176168. PubMed ID: 38059442
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
12. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R; Ambwani SR; Singh S
Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
[TBL] [Abstract][Full Text] [Related]
15. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
Pertwee RG
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
[TBL] [Abstract][Full Text] [Related]
16. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
17. The synthetic CB
Coronado-Álvarez A; Romero-Cordero K; Macías-Triana L; Tatum-Kuri A; Vera-Barrón A; Budde H; Machado S; Yamamoto T; Imperatori C; Murillo-Rodríguez E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110301. PubMed ID: 33741446
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of cannabinoids in CNS disease.
Croxford JL
CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
[TBL] [Abstract][Full Text] [Related]
19. Receptor mechanisms underlying the CNS effects of cannabinoids: CB
Hempel B; Xi ZX
Adv Pharmacol; 2022; 93():275-333. PubMed ID: 35341569
[TBL] [Abstract][Full Text] [Related]
20. Synthetic cannabinoids JWH-018, JWH-122, UR-144 and the phytocannabinoid THC activate apoptosis in placental cells.
Almada M; Alves P; Fonseca BM; Carvalho F; Queirós CR; Gaspar H; Amaral C; Teixeira NA; Correia-da-Silva G
Toxicol Lett; 2020 Feb; 319():129-137. PubMed ID: 31730886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
